| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 06/04/2009 | US20090142426 Aqueous Extract of Tobacco Leaves, Its Uses in the Treatment of Dependence |
| 06/04/2009 | US20090142423 Use of extracts or extractants of the guajacum types, said extracts or extractants bringing about phosphodiesterase-4 inhibition and method for producing the same |
| 06/04/2009 | US20090142405 Bioactive agent, a low molecular weight chitosan, and a negatively charged third component; the chitosan dominates on the nanoparticle surface; enhanced permeability for paracellular drug delivery; chewable composition |
| 06/04/2009 | US20090142401 Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release |
| 06/04/2009 | US20090142329 Interleukin-1 Beta Converting Enzyme Like Apoptosis Protease-3 and 4 |
| 06/04/2009 | US20090142296 Method of increasing trafficking of endothelial progenitor cells to ischemia-damaged tissue |
| 06/04/2009 | US20090142270 Prevention and treatment of cerebral amyloid angiopathy |
| 06/04/2009 | CA2744736A1 Compositions comprising nicotinic agonists and methods of using same |
| 06/04/2009 | CA2706986A1 Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
| 06/04/2009 | CA2706974A1 Novel carboxylic acid 4-phenylazo-phenyl ester derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 06/04/2009 | CA2706866A1 Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10 |
| 06/04/2009 | CA2706775A1 Crystal forms of o-desmethylvenlafaxine fumarate |
| 06/04/2009 | CA2706656A1 Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition |
| 06/04/2009 | CA2706333A1 Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the .beta.2 adrenergic receptor |
| 06/04/2009 | CA2706300A1 Human monoclonal nicotine specific antibodies |
| 06/04/2009 | CA2706171A1 Fused indane compound |
| 06/04/2009 | CA2705408A1 New therapeutic approaches for treating cmt and related disorders |
| 06/04/2009 | CA2703561A1 Novel polymorphic form of rotigotine and process for production |
| 06/04/2009 | CA2702437A1 Method of delaying the onset of clinically definite multiple sclerosis |
| 06/04/2009 | CA2694572A1 Drug for alleviating motor complications or psychiatric symptoms of parkinson's disease |
| 06/03/2009 | EP2065463A2 Survival and development of neural cells |
| 06/03/2009 | EP2065401A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 06/03/2009 | EP2065400A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 06/03/2009 | EP2065398A1 Human monoclonal nicotine specific antibodies |
| 06/03/2009 | EP2065366A2 HIF hydroxylase inhibitors |
| 06/03/2009 | EP2065053A1 Cell death inhibitor |
| 06/03/2009 | EP2065041A1 Use of medium chain triglycerides for the treatment and prevention of Parkinson's disease, Huntington' disease or Amyloid Lateral Sclerosis resulting from reduced neuronal metabolism |
| 06/03/2009 | EP2065038A1 New therapeutic approaches for treating Charcot-Marie-Tooth disease |
| 06/03/2009 | EP2064213A1 Heteroaryl derivatives as protein kinase inhibitors |
| 06/03/2009 | EP2064207A2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| 06/03/2009 | EP2064206A2 Crystalline forms of tiagabine hydrochloride and processes for the preparation of amorphous tiagabine hydrochloride |
| 06/03/2009 | EP2064194A2 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| 06/03/2009 | EP2064191A1 Aspartyl protease inhibitors |
| 06/03/2009 | EP2064186A1 Azabicyclic compounds as inhibitors of monoamines reuptake |
| 06/03/2009 | EP2064185A1 1h-quinolin-4-one compounds, with affinity for the gaba receptor, processes, uses and compositions |
| 06/03/2009 | EP2063962A2 Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
| 06/03/2009 | EP2063902A1 Therapeutic cell medicine comprising skin tissue derived stem cell |
| 06/03/2009 | EP2063894A2 Formulations containing pyridazine compounds for treating neuroinflammatory diseases |
| 06/03/2009 | EP2063892A2 Methods and compositions for treating amyotrophic lateral sclerosis (als) |
| 06/03/2009 | EP2063889A2 Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
| 06/03/2009 | EP2063886A2 Use of n-containing spirocompounds for the enhancement of cognitive function |
| 06/03/2009 | EP2063880A2 Composition for the treatment of amyotrophic lateral sclerosis |
| 06/03/2009 | EP2063875A2 Combination pharmaceutical compositions |
| 06/03/2009 | EP2063865A1 Long term 24 hour intestinal administration of levodopa/carbidopa |
| 06/03/2009 | EP1910381B1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-on- compounds and the use thereof for producing drugs |
| 06/03/2009 | EP1786790B1 Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses |
| 06/03/2009 | EP1648431B1 Novel use of a polyamine-poor composition for the production of a medical human food |
| 06/03/2009 | EP1608350B1 Methods of preventing, treating and diagnosing disorders of protein aggregation |
| 06/03/2009 | EP1480618B1 Sustained release drug formulations containing a carrier peptide |
| 06/03/2009 | EP1399440B1 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors |
| 06/03/2009 | EP1263720B1 Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same |
| 06/03/2009 | EP1253853B1 Method for classifying physiologic brain imbalances using quantitative eeg |
| 06/03/2009 | EP1218544B1 TAR RNA binding peptides |
| 06/03/2009 | CN101445504A Dioxane-2-alkyl carbamates derivatives |
| 06/03/2009 | CN101445494A Conjugated psychotropic drugs and uses thereof |
| 06/03/2009 | CN101445463A Beta2-adrenergic receptor agonists |
| 06/03/2009 | CN101444519A Therapeutic methods and delivery systems utilizing sex steroid precursors |
| 06/03/2009 | CN101444509A Triple monoamine reuptake inhibitors for the treatment of chronic pain |
| 06/03/2009 | CN101444498A Use of retigabine or its medical salts for the treatment of neuropathic pain |
| 06/03/2009 | CN101444496A Compounds for the treatment of metabolic disorders |
| 06/03/2009 | CN100494190C Compound containing o-naphthaquinone and application |
| 06/03/2009 | CN100494182C Regulatory factor of tumor necrosis alpha factor |
| 06/03/2009 | CN100493613C A method to improve surface properties of pharmaceutical tablets |
| 06/03/2009 | CN100493501C Scopolamine hydrobromide dry powder inhalant for nose and preparing method |
| 06/03/2009 | CN100493494C American ginseng oral disintegration tablet and its preparing process |
| 06/02/2009 | US7541465 Substituted 2-aminoacetamides and the use thereof |
| 06/02/2009 | US7541378 tert-butyl 3-amino-1H-thieno[2,3-c]pyrazole-5-carboxylate; N-benzyl-3-[(4-fluorobenzoyl)amino]-1H-thieno[2,3-c]pyrazole-5-carboxamide; treats a disease caused associated with an altered (disregulated) protein kinase activity e.g cancer, cell proliferative disorders, Alzheimer's disease, viral infections |
| 06/02/2009 | US7541376 3-(3-Fluoro-phenyl)-6-methoxy-1H-indazole-5-carboxylic acid(furan-2-ylmethyl)-amide; 3-Benzo[b]thiophen-2-yl-4-methoxy-1H-indazole-5-carboxylic acid[3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide; Jun amino-terminal kinase (JNK) inhibitor; immunologic disease, inflammatory and neurodegenerative diseases |
| 06/02/2009 | US7541375 Azole derivatives and pharmaceutical compositions containing them |
| 06/02/2009 | US7541369 Amino-derivatives as novel inhibitors of histone deacetylase |
| 06/02/2009 | US7541363 (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione; excellent solubility, stability, bioavailability, dispersing property; adenosine A2 receptor antagonistic activity; treats Parkinson disease, senile dementia, depression, asthma and osteoporosis |
| 06/02/2009 | US7541362 7-(3,4-Dichlorophenyl)-4,7-dihydro-5-methyl-6-(5-phenyl-2-oxazolyl)pyrazolo[1, 5-a]pyrimidine |
| 06/02/2009 | US7541358 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| 06/02/2009 | US7541355 Conversion process for 2,3-benzodiazepine enantiomers |
| 06/02/2009 | US7541354 Bicyclo-pyrazoles |
| 06/02/2009 | US7541337 Methods and compositions for the treatment of peripheral artery disease |
| 06/02/2009 | US7541189 complex of a certain ARNT family transcription coupling factor and a certain transcription regulatory factor with ability of exerting a promotive activity on the CME sequence; Down's syndrome |
| 06/02/2009 | US7541033 Humanized anti-IL-1β antibodies |
| 06/02/2009 | US7541031 Methods for treating rheumatoid arthritis using human antibodies that bind human TNFα |
| 06/02/2009 | CA2450787C Active ingredient combination for pharmacological addictive substance or intoxicant therapy |
| 06/02/2009 | CA2433833C Use of flumazenil in developing a drug for the treatment of alcohol dependence |
| 06/02/2009 | CA2394606C New modulators of dopamine neurotransmission |
| 06/02/2009 | CA2387143C Transdermal therapeutic system containing tulobuterol hydrochloride for administering the bronchodilator tulobuterol via the skin |
| 06/02/2009 | CA2349719C Controlled delivery of antidepressants |
| 06/02/2009 | CA2334308C Hyperforin derivatives, the use thereof and formulations containing them |
| 06/02/2009 | CA2258539C Ring-fused dihydropyranes, process for the preparation and use thereof |
| 05/30/2009 | CA2612999A1 Modified release composition of at least one form of venlafaxine |
| 05/28/2009 | WO2009067607A2 Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders |
| 05/28/2009 | WO2009067586A1 Biaryl substituted diazabicycloalkane derivatives |
| 05/28/2009 | WO2009067579A1 Biaryl substituted azabicyclic alkane derivatives as nicotinic acetylcholine receptor activity modulators |
| 05/28/2009 | WO2009067535A1 Topical composition for treating pain |
| 05/28/2009 | WO2009067406A1 Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
| 05/28/2009 | WO2009067405A1 Substituted pyrazinyl amide compounds as modulators of the histamine h3 receptor |
| 05/28/2009 | WO2009067401A1 Cycloalkyloxy-and hetξrocycloalky- loxypyridine compounds as modulators of the histamine h3 receptor |
| 05/28/2009 | WO2009066752A1 Plastic container having cyclic polyolefin layer |
| 05/28/2009 | WO2009066685A1 Sense-improving agent |
| 05/28/2009 | WO2009066457A1 External preparation composition comprising fatty acid-based ionic liquid as active ingredient |
| 05/28/2009 | WO2009066325A1 Controlled release pharmaceutical compositions of pregabalin |
| 05/28/2009 | WO2009066138A2 Stabilization of vitamin b complex and lidocaine hydrochloride injection |
| 05/28/2009 | WO2009065946A2 Pharmaceutical kit consisting of an oil-in-water emulsion and a solid composition |